Articles tagged with Antibodies
A study published in PLOS Pathogens found that older individuals are more susceptible to West Nile virus due to impaired immune responses. The researchers discovered that older mice had delayed antibody responses, reduced helper T cells, and lower chemokine levels, leading to higher viral loads and increased brain damage.
A new database, Histone Antibody Specificity Database, has been launched to improve the accuracy of histone antibodies used in epigenetics research. The database provides validated test results for over 100 commonly used antibodies, allowing researchers to select reliable options for their experiments.
A new online portal provides a robust online interactive database to address the 'antibody crisis' in molecular biology. The Histone Antibody Specificity Database allows scientists to find reliable antibodies for their research with higher confidence, using validated test results.
A phase 2 trial found that AS03 and MF59 adjuvants increased immune responses to an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest antibody response. The study suggests AS03 as a first-line adjuvant for H7N9 vaccines in adults.
Researchers at Rockefeller University discovered that high affinity B cells divide faster during the antibody selection process, giving them an advantage. This discovery builds on earlier work and may have important implications for improving vaccines and understanding lymphomas.
A University of Toronto research team discovered a new link between the genetic cause of ALS and its pathology, suggesting that C9orf72's mislocalization leads to TDP-43 buildup. This breakthrough offers new avenues for research and potential treatment or cure.
Researchers have discovered a subset of plasma cells in the bone marrow that serve as an immune archive, preserving a catalog of how the body responded to measles and mumps viruses in childhood. These long-lived cells can provide valuable insights for vaccine designers aiming to create long-lasting antibodies.
Vanderbilt University Medical Center researchers have developed a large panel of antibody treatments against chikungunya, a flu-like illness with debilitating joint pain. The antibodies can be used to treat infected individuals early in the infection, potentially preventing severe symptoms.
Researchers discovered a link between autoimmune diseases and Long QT syndrome, a potentially life-threatening heart condition. Screening and counseling are now recommended for patients with certain medications or abnormal electrolytes.
A new study found that a test can predict which rheumatoid arthritis patients will fail to respond to biologic drugs. Detecting low drug levels and anti-drug antibodies in the bloodstream can help adjust treatments.
Researchers discovered a human antibody specific to dengue virus serotype 2 that protects mice from the virus, regardless of administration timing. The antibody may act as both a preventative and therapeutic agent by locking viral envelope proteins on the surface, preventing them from entering host cells.
Researchers developed a new method to map critical chemical tags on proteins, enabling better understanding of protein formation and function. The technique allows pinpointing phosphates' location and studying unstable amino acids like histidine.
A team led by Associate Professor Shee-Mei Lok at Duke-NUS Medical School discovered an antibody that neutralizes dengue virus serotype 2 (DENV-2), making it harder to kill. The finding could help develop dengue therapeutics and is a significant step towards addressing the global dengue pandemic.
A Stanford study found that narcolepsy may be triggered by a combination of genetic predisposition and infection, particularly with the H1N1 virus. Researchers discovered elevated antibodies in patients who received the Pandemrix flu vaccine, which was associated with an increased risk of narcolepsy.
Researchers at Scripps Research Institute identify new immune molecules that protect against deadly Marburg virus, a relative of Ebola virus. The study provides ingredients needed to develop treatments for future Marburg outbreaks.
Researchers at The Wistar Institute identified specific mutations in H3N2 viruses that made the 2014-2015 flu vaccine less effective. Antigenic drift, a phenomenon where viruses accumulate mutations to evade immune response, was found to be a key factor.
A single mutation in the H3N2 virus helped it evade the immune system's defenses, making last year's flu vaccine less effective. Researchers have identified this mutation as a key factor in the mismatch between the vaccine strain and circulating strains.
Researchers uncover detailed information on AnAPN1 protein shape and antibody binding sites, enabling the design of more effective mosquito-based vaccines. This breakthrough may lead to a reduced number of infected mosquitoes and eventual disease eradication.
Zhiqiang An received a grant to research how tumors evade therapy, aiming to develop countermeasures for improved immunotherapy success and reduced mortality. The focus is on a type of leukemia affecting tens of thousands in the US.
Researchers found that patients positive for HPV16 E1, E4-7, L1, L2, and E2 antibodies had better overall and progression-free survival compared to those negative. This suggests that these antibodies may be used to identify patients at risk of oropharyngeal cancer recurrence and death.
Scientists developed ICeChIP, a new technique to calibrate chromatin immunoprecipitation (ChIP) experiments with an internal standard. This improves accuracy and reproducibility in epigenetic studies, enabling comparisons between experiments and discovery of new findings, including the prevalence of bivalency in stem cells.
Researchers discovered that Hepatitis C virus variants work together, sacrificing some to protect others from the immune system. This complex interaction, known as antigenic cooperation, could alter vaccine and treatment strategies.
Researchers have discovered a novel antibody insecticide that targets the African malaria mosquito, offering an alternative control strategy to halt the spread of the disease. The antibodies work by targeting a key component of the mosquito's nervous system, killing over 90% of infected insects within a day.
A novel antibody, Ab926, has been discovered that can prevent E. coli from attaching to human cell surfaces and also dislodge bacteria already attached. This antibody works by binding to the side of the FimH pocket, rather than directly competing with free-floating mannose.
A Case Western Reserve University researcher has won a $500,000 NSF CAREER grant to develop tiny sensors capable of detecting insecticides in Lake Erie or determining subtypes of human cancers. The technology combines antibodies with plant viruses to create a large surface area for targeting pollutants or cancer cells.
Scientists at MIT created a new cancer therapy that activates both the innate and adaptive immune systems to attack tumors. The treatment combines an antibody drug with IL-2, which boosts immune responses, resulting in complete tumor disappearance in 80-90% of mice.
Researchers at Texas Biomedical are exploring a novel mechanism for Filovirus detection using llama antibodies, which could lead to more sensitive diagnostic tools for Marburg and Ebola viruses. The goal is to develop streamlined tests that can detect all known and emerging strains of these viruses.
A Phase 1 trial of VSV-ZEBOV, an experimental Ebola vaccine, found it safe and elicited robust antibody responses in all 40 healthy adults who received it. The vaccine showed a favorable safety profile with mild or moderate fever experienced by 30% of participants.
Researchers found that camel antibodies protected uninfected mice from MERS and helped infected mice expunge the disease. The study suggests these antibodies might be therapeutic for MERS patients and protect uninfected household members and healthcare workers.
Researchers at CRT and Bioinvent are developing antibodies targeting OX40 and 4-1BB, 'co-receptors' that stimulate killer T-cells. The goal is to reverse tumour cell suppression of immune responses, allowing the immune system to fight cancer.
Researchers at NYU College of Dentistry are working with Rheonix, Inc. on a Phase II grant to develop an affordable point-of-care test for HIV/AIDS detection in remote areas. The test aims to detect both antibodies and viral RNA in a single specimen within under one hour.
A multivalent vaccine candidate induced broad antibody responses in trial participants, including to non-vaccine strains, suggesting a possible solution to evading immunity. The study provides evidence that VLP-based vaccines may overcome antigenic drift, but further development and clinical trials are needed for a vaccine suitable for...
Researchers report significant recovery after a single dose of an experimental treatment targeting interleukin-23, a key immune signaling protein in psoriasis. The study found nearly all patients experienced dramatic improvement in their symptoms, with an average 80% reduction in skin lesions.
Researchers found increased pocket depth and clinical attachment loss in patients with rheumatoid arthritis, highlighting the link between gum disease and joint inflammation. The study also identified Porphyromonas gingivalis antibodies as biomarkers for identifying patients who may benefit from periodontal treatment.
Researchers have successfully treated dogs with hemophilia using a mutant human protein with unusually high blood-clotting power. The treatment eliminated pre-existing antibodies and reversed the bleeding disorder in two years without causing thrombosis or immune reactions.
Recent research suggests that irisin, believed to travel from muscle to fat tissue after exercise, may not exist in humans. New tests used in previous studies found antibodies were poorly vetted and nonspecific, leading to false positive results.
A new study has identified antibodies targeting dopamine D2 receptors and NMDA glutamate receptors in children experiencing their first episode of psychosis. This finding suggests that autoimmunity may play a role in the development of psychosis, offering hope for new treatment approaches.
Researchers have developed an antibody called FcDART that provides 100% protection against the H5N1 influenza virus in ferrets and mice. This breakthrough could lead to the development of vaccines to match each flu virus and protect vulnerable populations.
A new study suggests that adults over 30 only get the flu about twice a decade, according to researchers who analyzed blood samples from volunteers in Southern China. The study found that flu-like illnesses can be caused by many pathogens, making it difficult to assess infection frequency.
A Scripps Research Institute team has discovered an antibody that can target both Marburg and Ebola viruses, paving the way for new treatment options. The antibody works by binding to a vulnerable site on the virus's surface, preventing it from entering human cells.
A collaborative team identified mechanisms involved in antibody response to the Marburg virus by studying a survivor's blood. The study reveals that the human immune system can effectively fight Marburg virus infections by producing antibodies.
Human antibodies have been isolated and characterized that can neutralize the Marburg virus, a close cousin to Ebola. The discovery could lead to the development of an effective treatment and vaccine against these often lethal viruses. Researchers hope to complete clinical safety trials by the end of the year.
Researchers found that certain bacterial DNA can be passed from mother to child, affecting traits such as immunity and inflammation. This discovery suggests a new factor in understanding how genes influence illness and health.
Scientists at NTU Singapore have developed an antibody that boosts survival chances for patients with influenza and pneumonia. The antibody, proven effective in lab tests, can also be used to develop a diagnostic kit to track treatment effectiveness.
George Mason University researchers have discovered peptides in alligator blood that can effectively fight bacterial infections. These peptides, part of the innate immunity system, could potentially be developed into new treatments for wound infections and biothreat agents.
Researchers fuse human hormones with cow antibodies to create long-lasting treatment options for hormone deficiencies and other diseases. The new therapy shows promise in reducing the frequency of injections needed for conditions like Turner syndrome and low birth weight.
A new TSRI study explains how booster shots prompt immune memory to improve, a crucial step toward longer-lasting vaccines. The research demonstrates how immune cells evolve and adapt to recognize viruses, leading to more diverse and effective antibody responses.
Researchers at Caltech develop antibody-based molecules that bind to and neutralize HIV more effectively than natural antibodies, offering a potential approach to engineer more effective HIV-fighting drugs. The breakthrough uses DNA as a molecular ruler to design novel molecules.
Researchers at Aarhus University have discovered ten new antibodies that can inhibit blood vessel formation near tumors, cutting off oxygen and nutrient supply. The antibodies appear to work effectively in laboratory tests and show promising therapeutic potential.
Researchers at NYU Polytechnic School of Engineering have developed a new colloidal gold test strip that demonstrates high detection sensitivity for cardiac troponin I (cTn-I) detection. The new strip uses microplasma-generated gold nanoparticles, attracting more antibodies and resulting in significantly higher detection sensitivity.
Researchers at McMaster University have discovered a new class of antibodies that can neutralize a wide range of influenza A viruses, paving the way for a universal flu vaccine. The vaccine would only need to be given once and could protect against all strains of flu, even when the virus mutates.
Researchers at TSRI have developed a more effective nicotine vaccine by targeting only the left-handed version of nicotine, eliciting four times as many antibodies. The new vaccine has shown promise in animal studies and could lead to treatments for smoking addiction.
Researchers at University of Cincinnati discover a new drug therapy that effectively lowers antibodies in kidney patients, paving the way for more successful kidney transplants. The study suggests this approach could benefit up to 10-20% of heart and pancreas transplant candidates who are currently ineligible due to high antibody levels.
Researchers found that endogenous retroviruses play a critical role in the body's immune defense against common bacterial and viral pathogens. The ERV DNA can activate B cells to produce protective antibodies, suggesting that these viruses have an 'physiological' function.
Researchers at Yale University have developed synthetic antibody mimics (SyAMs) that target disease cells and stimulate immune responses, offering potential for treating prostate cancer and other diseases.
Researchers at the University of Southampton have found that a specific form of antibody, IgG2B, is more effective at stimulating cancer immunity than others. By engineering antibodies into a locked B structure, they aim to create stronger immune stimulators for cancer patients.
A study found that seasonal flu vaccines protect against multiple flu strains, including those not included in vaccine formulations. The researchers also discovered that exposure to birds can elicit immune responses to avian influenza viruses in humans.
A study found that seasonal flu vaccines can induce strong immune responses against multiple flu virus subtypes, including some not included in vaccine formulations. This could provide protection against emerging pandemic strains from avian populations.
Research team led by Miguel Soares discovered that specific bacterial components in the human gut microbiota can trigger a natural defense mechanism against malaria. High levels of circulating anti-alpha-gal antibodies induced by vaccination are highly protective against malaria transmission.
Ramy Arnaout has been awarded a two-year grant to analyze antibody repertoires of over 1,000 Americans to clarify the link between antibodies, cardiovascular disease, and aging. The goal is to determine individual treatment needs for patients with cardiovascular disease.